Overview
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Status:
Recruiting
Recruiting
Trial end date:
2023-03-31
2023-03-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Phase 1 2-part study to evaluate the effect of food on pharmacokinetics of pelabresib (CPI-0610) and the effect of pelabresib on QTc in patients with advanced malignanciesPhase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Constellation Pharmaceuticals
Criteria
Inclusion Criteria:- 18 years of age or older
- Confirmed diagnosis of an advanced malignancy for which no effective standard
treatment options are available
- Eastern Cooperative Oncology Group (ECOG) performance status of <1
Exclusion Criteria:
- Chronic or active conditions and/or concomitant medication use that would prohibit
treatment